| abstract |
A compound comprising: a) a receptor binding moiety; b) a chelator; and c) an optional linking group between the receptor binding moiety and chelator; or pharmaceutically acceptable salts thereof; wherein: -the receptor binding moiety is a Leukotriene B4 (LTB4) receptor binding moiety, and -the compound has a binding affinity for LBT4 receptor of less than 1000nM -the LBT4 receptor binding moiety is not an antibody or a peptide. Also disclosed are kits comprising the compound described above, and optionally also containing other agents such as reducing agents or ancillary ligands (e.g. tricine and TPPTS). Also disclosed is a radio-labeled LBT4 binding agent, which comprises: a) the compound described above; b) a radioisotope selected from 99mTc, 111In, 95Tc, 62Cu, 67Ga, 68Ga, 123I, 125I, 18F, 11C, 13N, 15O, and 75Br. Also disclosed is a method of detecting sites of infection and inflammation in a mammal comprising administering to the mammal a radio-labeled LTB4 binding agent (as described above) and then detecting the sites using a radiation detecting probe or planar or ring gamma camera. Also disclosed are the compounds of formula: We' - O - (CR54R55)k" - Y' wherein: We' is a substituted pyridyl derivative as defined in the specification, or an optional substituted hydroxyphenyl derivative as defined in the specification; R54 and R55 are independently selected from the group: H, Alkyl, alkoxy, or R54 and R55 may be taken together to from a 3-6 membered cycloalkyl; k" is 4-7 Y' is selected from the group: C(=O)NHR56, NHC(=O)R56 and NHC(=O)NHR57 The compounds of formula We' - O - (CR54R55)k" - Y' are useful in the manufacture of a medicament for treating disease in a mammal associated with infection and disease. |